Scribe Therapeutics
Scribe Therapeutics is a Gene & Genome Editing Platforms company founded in 2018 and based in Alameda, United States. It has raised $120M in total funding, most recently a Series B in 2021.
Founded in 2018 by Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe Therapeutics engineers bespoke CRISPR enzymes rather than relying on natural Cas9 or Cas12. Its X-Editing (XE) platform produces enzymes optimized for precision, potency, and deliverability, designed specifically as a tooling layer for in vivo genetic medicines. Scribe runs a partner-driven model: its 2022 Sanofi collaboration for CRISPR cell therapies carries more than $1B in potential milestones, and the company has since expanded the deal toward in vivo programs for sickle cell and other genomic diseases, reaching an in vivo milestone in early 2025.
It treats CRISPR as a deeply engineered enzyme-design problem, selling that capability to large pharma partners.
scribetx.com ↗·Gene & Genome Editing Platforms·
United States·private 
